David Kirn, MD

David Kirn is a seasoned physician-scientist, medicines designer/developer, and biotech entrepreneur with over 25 years of expertise in the industry.

He has a strong focus on viral vector-based therapeutics, particularly gene therapy and oncolytic virus cancer immunotherapy, overseeing programs from design concept to Phase 3 clinical trials.

David Kirn is a co-founder and CEO of multiple viral vector-based therapeutic platform companies, leveraging his knowledge and experience in the field.

With an educational background that includes a Doctor of Medicine (MD) from the University of California, San Francisco, and business training from the University of California, Berkeley, Haas School of Business, he is well-equipped to navigate the intersection of medicine and business.

In addition to his entrepreneurial ventures, David Kirn is actively involved in academia, serving as a Professor at UC Berkeley, teaching and mentoring students in biotech entrepreneurship.

He has held various key positions in prestigious organizations, both in the academic and corporate sectors, such as Life Sciences Entrepreneurship Center at UC Berkeley, Bakar Labs, Robinson Life Sciences Business & Entrepreneurship, and more.

David Kirn's vast experience includes roles such as Founder & CEO at Jennerex Biotherapeutics, J & J Entrepreneur Innovator at Johnson & Johnson, and SVP of Global Clinical R&D at Celgene, showcasing his diverse skill set and leadership capabilities in the biotech industry.

His contributions to viral vector gene therapy, oncolytics, and cancer immunotherapy have made him a respected figure in the field, with a track record of successful innovations and leadership.

Through his work at IGNITE Immunotherapy, 4D Molecular Therapeutics, and other ventures, David Kirn has cemented his reputation as a pioneering figure in advancing therapeutic solutions for complex medical challenges.

David Kirn's profile reflects a rich tapestry of experience, blending academic rigor, clinical expertise, and entrepreneurial acumen to drive advancements in biotechnology and healthcare.

As a thought leader and industry expert, David Kirn continues to inspire and shape the future of biotech innovation with his multidisciplinary approach and dedication to improving patient outcomes.